Search Within

Population Sciences Research Program

  1. "Journal article"
  2. "Malin Hultcrantz"
Formats
  1. Journal Article (13)
Groups
  1. Center for Hematologic Malignancies (13)
  2. Department of Medicine (13)
  3. Hematologic Malignancies, Division of (13)
  4. Myeloma (13)
  5. Sloan Kettering Institute Postdocs (13)
  6. Biostatistics Service (12)

More Groups

People
  1. Malin Hultcrantz (13)
  2. Andriy Derkach (12)
  3. Alexander Lesokhin (10)
  4. Urvi Shah (10)
  5. Carlyn Rose Tan (9)
  6. Hani Hassoun (9)

More People

Years
  1. 2024 (1)
  2. 2023 (3)
  3. 2022 (3)
  4. 2021 (5)
  5. 2020 (1)
Publications
  1. Clinical Cancer Research (2)
  2. Nature Communications (2)
  3. American Journal of Hematology (1)
  4. Blood Advances (1)
  5. Blood Cancer Discovery (1)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Association for Cancer Research (3)
  2. Nature Publishing Group (3)
  3. American Medical Association (1)
  4. American Society of Hematology (1)
  5. Elsevier Inc. (1)
  6. Elsevier Science, Inc. (1)

More Publishers

Results (13)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
    Journal Article

    Shah, U. A.; Moshier, E.; Derkach, A.; Huang, Y.; Mailankody, S.; Tan, C. R.; Maclachlan, K.; Hultcrantz, M.; Korde, N.; Hassoun, H.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: A prospective observational cohort study
    Journal Article

    Korde, N.; Tavitian, E.; Mastey, D.; Lengfellner, J.; Hevroni, G.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; more...
    eClinicalMedicine (2023)

    Fulltext@MSK | Save
  • Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach
    Journal Article

    Pianko, M. J.; Tiutan, T.; Derkach, A.; Flynn, J.; Salvatore, S. P.; Jaffer-Sathick, I.; Rossi, A. C.; Lahoud, O.; Hultcrantz, M.; Shah, U. A.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets
    Journal Article

    Shah, U. A.; Maclachlan, K. H.; Derkach, A.; Salcedo, M.; Barnett, K.; Caple, J.; Blaslov, J.; Tran, L.; Ciardiello, A.; Burge, M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Refractive shifts and changes in corneal curvature associated with antibody-drug conjugates
    Journal Article

    Canestraro, J.; Hultcrantz, M.; Modi, S.; Hamlin, P. A.; Shoushtari, A. N.; Konner, J. A.; Tew, W. P.; Iyengar, N. M.; Heinemann, M.; Abramson, D. H.; more...
    Cornea (2022)

    Fulltext@MSK | Save
  • Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
    Journal Article

    Piedra, K.; Peterson, T.; Tan, C.; Orozco, J.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Lesokhin, A.; Shah, U.; Lu, S.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
    Journal Article

    Maclachlan, K. H.; Rustad, E. H.; Derkach, A.; Zheng-Lin, B.; Yellapantula, V.; Diamond, B.; Hultcrantz, M.; Ziccheddu, B.; Boyle, E. M.; Blaney, P.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save